NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing
November 15, 2023 07:00 ET
|
NMD Pharma
Proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease In...
NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing
November 15, 2023 01:00 ET
|
NMD Pharma
Proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease In...
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
October 03, 2023 07:00 ET
|
NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
October 03, 2023 01:00 ET
|
NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
September 26, 2023 07:00 ET
|
NMD Pharma
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26 September 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small...
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy
September 26, 2023 01:00 ET
|
NMD Pharma
NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Aarhus, Denmark, 26 September 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small...
NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association
September 08, 2023 07:00 ET
|
NMD Pharma
NMD Pharma to host a Satellite Symposium* and present new clinical data at the 148th Annual Meeting of the American Neurological Association NMD Pharma to host a satellite symposium* at the...
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
June 20, 2023 07:00 ET
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2
June 20, 2023 01:00 ET
|
NMD Pharma
NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish, for the...
NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy
June 01, 2023 07:00 ET
|
NMD Pharma
Daniel Brennan brings over 25 years of strategic commercial experience leading public and private rare disease and CNS biopharma companies Aarhus, Denmark, 1 June 2023 – NMD Pharma A/S, a...